Skip to main content
Publications
Ribera A, Gimenez E, Oristrell G, Osorio D, Marsal JR , Garcia-Perez L, Ballesteros M, Rodenas E, Belahnech Y, Escalona R, Rivas N, Roca-Luque I, Ferreira-Gonzalez I, Espallargues M. Cost-effectiveness of implantable cardioverter-defibrillators for primary prevention of sudden cardiac death . Rev Esp Cardiol (Engl Ed). 2022 Jan;75(1):12-21. doi: 10.1016/j.rec.2021.05.004
Galian-Gay L, Gordon B, Marsal JR , Rafecas A, Pijuan Domenech A, Castro MA, Subirana Domenech MT, Sureda C, Miranda B, Marti G, Garcia-Dorado D, Dos Subira L. Determinants of long-term outcome of repaired pulmonary valve stenosis . Rev Esp Cardiol (Engl Ed). 2020 Feb;73(2):131-8.
Mazurek M, Halperin JL, Huisman MV, Diener HC, Dubner SJ, Ma CS, Rothman KJ , Healey JS, Teutsch C, Paquette M, Franca LR, Lu S, Bartels DB, Lip GYH. Antithrombotic treatment for newly diagnosed atrial fibrillation in relation to patient age: the GLORIA-AF registry programme . Europace. 2020 Jan 1;22(1):47-57. doi: 10.1093/europace/euz278
Luo C, Sun J, Liu D, Sun B, Miao L, Musetti S , Li J, Han X, Du Y, Li L, Huang L, He Z. Self-assembled redox dual-responsive prodrug-nanosystem formed by single thioether-bridged paclitaxel-fatty acid conjugate for cancer chemotherapy . Nano Lett. 2016 Sep 14;16(9):5401-8. doi: 10.1021/acs.nanolett.6b01632
Huisman MV, Ma CS, Diener HC, Dubner SJ, Halperin JL, Rothman KJ , Teutsch C, Schoof N, Kleine E, Bartels DB, Lip GY. Antithrombotic therapy use in patients with atrial fibrillation before the era of non-vitamin K antagonist oral anticoagulants: the Global Registry on Long-Term Oral Antithrombotic Treatment in Patients with Atrial Fibrillation (GLORIA-AF) phase I cohort . Europace. 2016 Sep;18(9):1308-18. doi: 10.1093/europace/euw073
Julvez J, Paus T, Bellinger D, Eskenazi B, Tiemeier H, Pearce N, Ritz B, White T, Ramchandani P, Gispert JD, Desrivieres S, Brouwer R, Boucher O, Alemany S, Lopez-Vicente M, Suades-Gonzalez E, Forns J , Grandjean P, Sunyer J. Environment and brain development: challenges in the global context . Neuroepidemiology. 2016;46(2):79-82. doi: 10.1159/000442256
Samelson EJ, Miller PD, Christiansen C, Daizedeh NS, Grazette L, Anthony MS , Egbuna O, Wang A, Siddhanti SR, Cheung AM, Franchimont N, Kiel DP. RANKL inhibition with denosumab does not influence 3-year progression of aortic calcification or incidence of adverse cardiovascular events in postmenopausal women with osteoporosis and high cardiovascular risk . J Bone Miner Res. 2014 Feb;29(2):450-7. doi: 10.1002/jbmr.2043